Structure, chemistry and pharmacology of naphthoflavones

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1357-1368

  Cui, Jiahua ^a   Li, Shaoshun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anticancer; Cystic fibrosis therapy; Flavonoids; Naphthoflavones; Pharmacology; Sars

Indexed keywords

2 HYDROXY 3,4 BENZOCHALCONE; 2 HYDROXY 5,6 BENZOCHALCONE; 4 IMIDAZOLYL 7,8 BENZOFLAVAN; 5,6 BENZOFLAVAN 4 OL; 7,8 BENZOTHIOFLAVONE; 7,8-BENZOFLAVAN 4 OL; 9 HYDROXY 7,8 BENZOFLAVONE; ALPHA NAPHTHOFLAVONE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; AROMATIC HYDROCARBON RECEPTOR; BETA NAPHTHOFLAVONE; BREAST CANCER RESISTANCE PROTEIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; DOCETAXEL; FLAVONOID; FUMITREMORGIN C; GAMMA NAPHTHOFLAVONE; HYPOXIA INDUCIBLE FACTOR 1BETA; MITOXANTRONE; NAPHTHOFLAVONE DERIVATIVE; NUCLEOSIDE TRANSPORTER; PHLORIZIN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BREAST CANCER; CHEMISTRY; CYSTIC FIBROSIS; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; METABOLISM; NONHUMAN;

ANIMALS; FLAVONES; HUMANS; MOLECULAR STRUCTURE;

EID: 84881490536     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313090010     Document Type: Article

References (119)

1. Harborne, J. B.; Williams, C. A. Advances in flavonoid research since 1992. Phytochemistry, 2000, 55, 481-504.
2. Havsteen, B. H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther., 2002, 96, 67-202.
3. Bowden, G. T.; Slaga, T. J.; Shapas, B. G.; Boutwell, R. K. The role of aryl hydrocarbon hydroxylase in skin tumor initiation by 7,12-dimethylbenz(a)anthracene and 1,2,5,6-dibenzanthracene using DNA binding and thymidine-3H incorporation into DNA as criteria. Cancer Res., 1974, 34, 2634-2642.
4. Diamond, L.; McFall, R.; Miller, J.; Gelboin, H. V. The effects of two isomeric benzoflavones on aryl hydrocarbon hydroxylase and the toxicity and carcinogenicity of polycyclic hydrocarbons. Cancer Res., 1972, 32, 731-736.
5. Gelboin, H. V.; Wiebel, F.; Diamond, L. Dimethylbenzanthracene tumorigenesis and aryl hydrocarbon hydroxylase in mouse skin: inhibition by 7,8-benzoflavone. Science, 1970, 170, 169-171.
6. Nesnow, S. A preliminary structure-activity study of the mixedfunction oxidase inhibitor 7,8-benzoflavone. J. Med. Chem., 1979, 22, 1244-1247.
7. Koley, A. P.; Buters, J. T. M.; Robinson, R. C.; Markowitz, A.; Friedman, F. K. Differential mechanisms of cytochrome P450 inhibition and activation by naphthoflavone. J. Bio. Chem., 1997, 272, 3149-3152.
8. Shimada, T.; Yamazaki, H.; Foroozesh, M.; Hopkins, N. E.; Alworth, W. L.; Guengerich, F. P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol., 1998, 11, 1048-1056.
9. Kellis, J. T., Jr.; Vickery, L. E. Inhibition of human estrogen synthetase (aromatase) by flavones. Science, 1984, 225, 1032-1034.
10. Cutroneo, K. R.; Seibert, R. A.; Bresnick, E. Induction of benzpyrene hydroxylase by flavone and its derivatives in fetal rat liver explants. Biochem. Pharmacol., 1972, 21, 937-945.
11. Zordoky, B. N.; El-Kadi, A. O. 2,3,7,8-Tetrachlorodibenzo-pdioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol. In. Vitro., 2010, 24, 863-871.
12. Galietta, L. J.; Springsteel, M. F.; Eda, M.; Niedzinski, E. J.; By, K.; Haddadin, M. J.; Kurth, M. J.; Nantz, M. H.; Verkman, A. S. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem., 2001, 276, 19723-19728.
13. Springsteel, M. F.; Galietta, L. J.; Ma, T.; By, K.; Berger, G. O.; Yang, H.; Dicus, C. W.; Choung, W.; Quan, C.; Shelat, A. A.; Guy, R. K.; Verkman, A. S.; Kurth, M. J.; Nantz, M. H. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotidebinding domain. Bioorg. Med. Chem., 2003, 11, 4113-4120.
14. Al-Nakkash, L.; Springsteel, M. F.; Kurth, M. J.; Nantz, M. H. Activation of CFTR by UCCF-029 and genistein. Bioorg. Med. Chem. Lett., 2008, 18, 3874-3877.
15. Zhang, S.; Yang, X.; Coburn, R. A.; Morris, M. E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol., 2005, 70, 627-639.
16. Waleh, N. S.; Murphy, B. J.; Zaveri, N. T. Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179. Cancer Lett., 2010, 289, 111-118.
17. Lin, A. S.; Nakagawa-Goto, K.; Chang, F. R.; Yu, D.; Morris- Natschke, S. L.; Wu, C. C.; Chen, S. L.; Wu, Y. C.; Lee, K. H. First total synthesis of protoapigenone and its analogues as potent cytotoxic agents. J. Med. Chem., 2007, 50, 3921-3927.
18. Mahal, H. S.; Venkataraman, K. Synthetical experiments in the chromone group. Part XIV. The action of sodamide on 1-acyloxy- 2-acetonaphthones. J. Chem. Soc., 1934, 1767-1769.
19. Bhalla, D. C.; Mahal, H. S.; Venkataraman, K. Synthetical experiments in the chromone group. Part XVII. Further observations on the action of sodamide on o-acyloxyacetophenous. J. Chem. Soc., 1935, 868-870.
20. Baker, W. 322. Molecular rearrangement of some oacyloxyacetophenones and the mechanism of the production of 3- acylchromones. J. Chem. Soc., 1933, 1381-1389.
21. Virkar, V. V.; Wheeler, T. S. 345. Chromones of the naphthalene series. Part II. Synthesis of linear naphthaflavone (6:7-benzoflavone). J. Chem. Soc., 1939, 1681-1683.
22. Bhullar, A. S.; Venkataraman, K. Synthetical experiments in the chromone group. Part II. 1:4-naphthapyrones. J. Chem. Soc., 1931, 1165-1170.
23. Menon, B. K.; Venkataraman, K. Synthetical experiments in the chromone group. Part IV. 1:4-naphthapyrones. J. Chem. Soc., 1931, 2591-2596.
24. Lv, Y.; Xia, P.; Li, G.; Cai, M. Studies on flavonoids VII. A novel synthesis of 5,6-benzoflavones. Journal of Beijing Medical University, 1988, 20 (2), 91-93.
25. Lv, Y.; Qin, H.; Zhang, L.; Li, G.; Cai, M. The synthesis of 7,8- benzoflavones. Chemistry, 1989, 6, 39-41.
26. Smith, F. E. A new preparation of 7: 8-benzoflavone (naphthaflavone). J. Chem. Soc., 1946, 542.
27. Khanna, M. S.; Singh, O. V.; Garg, C. P.; Kapoor, R. P. Oxidation of flavanones using thallium (III) salts: a new route for the synthesis of flavonest and isoflavonest. J. Chem. Soc., Perkin Trans., 1992, 2565-2568.
28. Namgoong, J. E.; Jeon, H. L.; Kim, Y. H.; Choi, M. G.; Chang, S. K. Hg2+-selective fluorogenic chemodosimeter based on naphthoflavone. Tetrahedron Lett., 2010, 51, 167-169.
29. Juvale, K.; Pape, V. F. S.; Wiese, M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg. Med. Chem., 2012, 20, 346-355.
30. Yahiaoui, S.; Fagnere, C.; Pouget, C.; Buxeraud, J.; Chulia, A. J. New 7,8-benzoflavanones as potent aromatase inhibitors: Synthesis and biological evaluation. Bioorg. Med. Chem., 2008, 16, 1474-1480.
31. Zaveri, N.; Waleh, N. Novel flavonoids as chemotherapeutic, chemopreventive, and antiangiogenic agents. U.S. Patent 2006/0264500 A1, November 23, 2006.
32. Lv, Y.; Liu, J.; Song, H.; Cai, M. Studies on flavonoids XIV. Synthesis of 5,6-benzoflavanone analogous in an one stage strategy. Chinese Science Bulletin, 1993, 38 (10), 913-916.
33. Yahiaoui, S.; Pouget, C.; Buxeraud, J.; Chulia, A. J.; Fagnere, C. Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors. Eur. J. Med. Chem., 2011, 46, 2541-2545.
34. Whitlock, J. P., Jr. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 103-125.
35. Beedanagari, S. R.; Bebenek, I.; Bui, P.; Hankinson, O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci., 2009, 110, 61-67.
36. Nukaya, M.; Moran, S.; Bradfield, C. A. The role of the dioxinresponsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc. Natl. Acad. Sci. USA, 2009, 106, 4923-4928.
37. Shimada, T.; Gillam, E. M.; Sutter, T. R.; Strickland, P. T.; Guengerich, F. P.; Yamazaki, H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug. Metab. Dispos., 1997, 25, 617-622.
38. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270, 414-423.
39. Wei, C.; Caccavale, R. J.; Kehoe, J. J.; Thomas, P. E.; Iba, M. M. CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer lett., 2001, 171, 113-120.
40. Goth-Goldstein, R.; Stampfer, M. R.; Erdmann, C. A.; Russell, M. Interindividual variation in CYP1A1 expression in breast tissue and the role of genetic polymorphism. Carcinogenesis, 2000, 21, 2119-2122.
41. Hakkola, J.; Pasanen, M.; Pelkonen, O.; Hukkanen, J.; Evisalmi, S.; Anttila, S.; Rane, A.; Mèantylèa, M.; Purkunen, R.; Saarikoski, S.; Tooming, M.; Raunio, H. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis, 1997, 18, 391-397.
42. Guengerich, F. P.; Shimada, T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res., 1998, 400, 201-213.
43. Ma, Q.; Lu, A. Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos., 2007, 35, 1009-1016.
44. Zhou, S. F.; Chan, E.; Zhou, Z. W.; Xue, C. C.; Lai, X.; Duan, W. Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr. drug metab., 2009, 10, 713-729.
45. Cavalieri, E. L.; Stack, D. E.; Devanesan, P. D.; Todorovic, R.; Dwivedy, I.; Higginbotham, S.; Johansson, S. L.; Patil, K. D.; Gross, M. L.; Gooden, J. K.; Ramanathan, R.; Cerny, R. L.; Rogan, E. G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA, 1997, 94, 10937-10942.
46. Kerlan, V.; Dreano, Y.; Bercovici, J. P.; Beaune, P. H.; Floch, H. H.; Berthou, F. Nature of cytochromes P450 involved in the 2-/4- hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol., 1992, 44, 1745-1756.
47. Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997, 57, 3026-31.
48. McFadyen, M. C.; Murray, G. I. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol., 2005, 1, 259-263.
49. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem., 2007, 282, 14348-14355.
50. Wang, A.; Savas, U.; Stout, C. D.; Johnson, E. F. Structural characterization of the complex between naphthoflavone and human cytochrome P450 1B1. J. Bio. Chem., 2011, 286, 5736-5743.
51. Cho, U. S.; Park, E. Y.; Dong, M. S.; Park, B. S.; Kim, K.; Kim, K. H. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2. Biochim. Biophys. Acta., 2003, 1648, 195-202.
52. Bauer, E.; Guo, Z.; Ueng, Y. F.; Bell, L. C.; Zeldin, D.; Guengerich, F. P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 1995, 8, 136-142.
53. Zhu, N.; Lightsey, D.; Foroozesh, M.; Alworth, W.; Chaudhary, A.; Willett, K. L.; Klein Stevens, C. L. Naphthoflavone propargyl ether inhibitors of cytochrome P450. J. Chem. Crystallogr., 2006, 36, 289-296.
54. Huang, R. S.; Duan, S.; Kistner, E. O.; Bleibel, W. K.; Delaney, S. M.; Fackenthal, D. L.; Das, S.; Dolan, M. E. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res., 2008, 68, 3161-3168.
55. McFadyen, M. C.; Melvin, W. T.; Murray, G. I. Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br. J. Cancer, 2004, 91, 966-971.
56. McFadyen, M. C.; McLeod, H. L.; Jackson, F. C.; Melvin, W. T.; Doehmer, J.; Murray, G. I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol., 2001, 62, 207-212.
57. Simpson, E. R.; Mahendroo, M. S.; Means, G. D.; Kilgore, M. W.; Hinshelwood, M. M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C. R.; Michael, M. D.; et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15, 342-355.
58. Hiscox, S.; Davies, E. L.; Barrett-Lee, P. Aromatase inhibitors in breast cancer. Maturitas, 2009, 63, 275-279.
59. Buzdar, A.; Howell, A.; Cuzick, J.; Wale, C.; Distler, W.; Hoctin- Boes, G.; Houghton, J.; Locker, G. Y.; Nabholtz, J. M. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol., 2006, 7, 633-643.
60. Gligorov, J.; Pritchard, K.; Goss, P. Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. Breast, 2007, 16, 1-9.
61. Smith, I. E.; Dowsett, M.; Ebbs, S. R.; Dixon, J. M.; Skene, A.; Blohmer, J. U.; Ashley, S. E.; Francis, S.; Boeddinghaus, I.; Walsh, G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol., 2005, 23, 5108-5116.
62. Kellis, J. T., Jr.; Nesnow, S.; Vickery, L. E. Inhibition of aromatase cytochrome P-450 (estrogen synthetase) by derivatives of alphanaphthoflavone. Biochem. Pharmacol., 1986, 35, 2887-2891.
63. Ibrahim, A. R.; Abul-Hajj, Y. J. Aromatase inhibition by flavonoids. J. Steroid Biochem. Mol. Biol., 1990, 37, 257-260.
64. Kao, Y. C.; Zhou, C.; Sherman, M.; Laughton, C. A.; Chen, S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ. Health Persp., 1998, 106, 85-92.
65. Dana P.; Petr H.; Stanislav S.; Barbora I.; Marie S. CYP19 activity modulation: small change of flavonoid structure result in inhibitorstimulator transition. In: 13th international conference on cytochrome P450 Biochemistry, Biophysics and Drug Metabolism, Prague, Czech Republic, June 29-July 03, 2003; pp. TP-09.
66. Noguchi, K.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliver. Rev., 2009, 61, 26-33.
67. Honjo, Y.; Hrycyna, C. A.; Yan, Q. W.; Medina-Perez, W. Y.; Robey, R. W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S. E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res., 2001, 61, 6635-6639.
68. Allen, J. D.; Schinkel, A. H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther., 2002, 1, 427-434.
69. Allen, J. D.; Jackson, S. C.; Schinkel, A. H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res., 2002, 62, 2294-9.
70. Doyle, L. A.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, 7340-7358.
71. Volk, E. L.; Farley, K. M.; Wu, Y.; Li, F.; Robey, R. W.; Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 2002, 62, 5035-5040.
72. Zhang, S.; Wang, X.; Sagawa, K.; Morris, M. E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos., 2005, 33, 341-348.
73. Ritzel, M. W.; Ng, A. M.; Yao, S. Y.; Graham, K.; Loewen, S. K.; Smith, K. M.; Ritzel, R. G.; Mowles, D. A.; Carpenter, P.; Chen, X. Z.; Karpinski, E.; Hyde, R. J.; Baldwin, S. A.; Cass, C. E.; Young, J. D. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem., 2001, 276, 2914-2927.
74. Errasti-murugarren, E.; Pastor-Anglada, M.; Casado, F. J. Role of CNT3 in the transepithelial flux of nucleosides and nucleosidederived drugs. J.Physiol., 2007, 582, 1249-1260.
75. Wang, C.; Pimple, S.; Buolamwini, J. K. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochem. Pharmacol., 2010, 79, 307-320.
76. de Wildt, S. N.; Kearns, G. L.; Leeder, J. S.; van den Anker, J. N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet., 1999, 37, 485-505.
77. Ueng, Y. F.; Kuwabara, T.; Chun, Y. J.; Guengerich, F. P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 1997, 36, 370-381.
78. Yun, C. H.; Shimada, T.; Guengerich, F. P. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res., 1992, 52, 1868-1874.
79. Shou, M.; Dai, R.; Cui, D.; Korzekwa, K. R.; Baillie, T. A.; Rushmore, T. H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Bio. Chem., 2001, 276, 2256-2262.
80. Wong, P. C.; Price, W. A., Jr.; Chiu, A. T.; Duncia, J. V.; Carini, D. J.; Wexler, R. R.; Johnson, A. L.; Timmermans, P. B. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 255, 211-217.
81. Lo, M. W.; Goldberg, M. R.; McCrea, J. B.; Lu, H.; Furtek, C. I.; Bjornsson, T. D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther., 1995, 58, 641-649.
82. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 1994, 33, 6450-6455.
83. Woods, C. M.; Fernandez, C.; Kunze, K. L.; Atkins, W. M. Allosteric activation of cytochrome P450 3A4 by alphanaphthoflavone: branch point regulation revealed by isotope dilution analysis. Biochemistry, 2011, 50, 10041-10051.
84. Roberts, A. G.; Atkins, W. M. Energetics of heterotropic cooperativity between α-naphthoflavone and testosterone binding to CYP3A4. Arch. Biochem. Biophys., 2007, 463, 89-101.
85. Harlow, G. R.; Halpert, J. R. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a sitedirected mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. USA, 1998, 95, 6636-6641.
86. Denison, M. S.; Pandini, A.; Nagy, S. R.; Baldwin, E. P.; Bonati, L. Ligand binding and activation of the Ah receptor. Chem. Biol. Interact., 2002, 141, 3-24.
87. Mimura, J.; Fujii-Kuriyama, Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta, 2003, 1619, 263-268.
88. Esser, C.; Rannug, A.; Stockinger, B. The aryl hydrocarbon receptor in immunity. Trends Immunol., 2009, 30, 447-54.
89. Reyes-Hernandez, O. D.; Mejia-Garcia, A.; Sanchez-Ocampo, E. M.; Castro-Munozledo, F.; Hernandez-Munoz, R.; Elizondo, G. Aromatic hydrocarbons upregulate glyceraldehyde-3-phosphate dehydrogenase and induce changes in actin cytoskeleton. Role of the aryl hydrocarbon receptor (AhR). Toxicology, 2009, 266, 30-17.
90. Elsherbiny, M. E.; El-Kadi, A. O.; Brocks, D. R. The effect of betanaphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicol. Lett., 2010, 195, 147-154.
91. Dewa, Y.; Nishimura, J.; Muguruma, M.; Jin, M.; Saegusa, Y.; Okamura, T.; Tasaki, M.; Umemura, T.; Mitsumori, K. beta- Naphthoflavone enhances oxidative stress responses and the induction of preneoplastic lesions in a diethylnitrosamine-initiated hepatocarcinogenesis model in partially hepatectomized rats. Toxicology, 2008, 244, 179-189.
92. Bradshaw, T. D.; Trapani, V.; Vasselin, D. A.; Westwell, A. D. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr. Pharm. Des., 2002, 8, 2475-2490.
93. Shertzer, H. G.; Genter, M. B.; Talaska, G.; Curran, C. P.; Nebert, D. W.; Dalton, T. P. 7H-dibenzo[c,g]carbazole metabolism by the mouse and human CYP1 family of enzymes. Carcinogenesis, 2007, 28, 1371-1378.
94. Yoshinari, K.; Okino, N.; Sato, T.; Sugatani, J.; Miwa, M. Induction of detoxifying enzymes in rodent white adipose tissue by aryl hydrocarbon receptor agonists and antioxidants. Drug Metab. Dispos., 2006, 34, 1081-1089.
95. Chatuphonprasert, W.; Sangkawat, T.; Nemoto, N.; Jarukamjorn, K. Suppression of beta-naphthoflavone induced CYP1A expression and lipid-peroxidation by berberine. Fitoterapia, 2011, 82, 889-895.
96. Fujita, Y.; Yonehara, M.; Tetsuhashi, M.; Noguchi-Yachide, T.; Hashimoto, Y.; Ishikawa, M. Beta-Naphthoflavone analogs as potent and soluble aryl hydrocarbon receptor agonists: improvement of solubility by disruption of molecular planarity. Bioorg. Med. Chem., 2010, 18, 1194-1203.
97. Gasiewicz, T. A.; Rucci, G. Alpha-naphthoflavone acts as an antagonist of 2,3,7, 8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Mol. Pharmacol., 1991, 40, 607-612.
98. Gasiewicz, T. A.; Kende, A. S.; Rucci, G.; Whitney, B.; Willey, J. J. Analysis of structural requirements for Ah receptor antagonist activity: ellipticines, flavones, and related compounds. Biochem. Pharmacol., 1996, 52, 1787-1803.
99. Santostefano, M.; Merchant, M.; Arellano, L.; Morrison, V.; Denison, M. S.; Safe, S. alpha-Naphthoflavone-induced CYP1A1 gene expression and cytosolic aryl hydrocarbon receptor transformation. Mol. Pharmacol., 1993, 43, 200-206.
100. Wilhelmsson, A.; Whitelaw, M. L.; Gustafsson, J. A.; Poellinger, L. Agonistic and antagonistic effects of alpha-naphthoflavone on dioxin receptor function. Role of the basic region helix-loop-helix dioxin receptor partner factor Arnt. J. Bio. Chem., 1994, 269, 19028-19033.
101. Zhao, B.; Nagy, S. R.; Baston, D. S.; Han, D.; Nantz, M.; Kurth, M.; Springsteel, M.; Denison, M. S. Screening and analysis of novel naphthoflavone ligands for the Ah receptor. Organohalogen Compounds, 2003, 65, 102-105.
102. Chiba, T.; Uchi, H.; Yasukawa, F.; Furue, M. Role of the arylhydrocarbon receptor in lung disease. Int. Arch. Allergy Immunol., 2011, 155 (Suppl 1), 129-134.
103. Lubet, R. A.; Heckman, B. M.; De Flora, S. L.; Steele, V. E.; Crowell, J. A.; Juliana, M. M.; Grubbs, C. J. Effects of 5,6- benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C? Oncol. Rep., 2011, 26, 731-736.
104. Bradshaw, T. D.; Bibby, M. C.; Double, J. A.; Fichtner, I.; Cooper, P. A.; Alley, M. C.; Donohue, S.; Stinson, S. F.; Tomaszewjski, J. E.; Sausville, E. A.; Stevens, M. F. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl) benzothiazoles. Mol. Cancer Ther., 2002, 1, 239-246.
105. Bradshaw, T. D.; Westwell, A. D. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr. Med. Chem., 2004, 11, 1009-1021.
106. Riordan, J. R.; Rommens, J. M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.L.; et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 1989, 245, 1066-1073.
107. Stern, M.; Geddes, D. M.; Alton, E. W. Taking stock of gene therapy for cystic fibrosis. Respir. Res., 2000, 1, 78-81.
108. Alton, E.; Kitson, C. Gene therapy for cystic fibrosis. Expert. Opin. Investig. Drugs, 2000, 9, 1523-1535.
109. Hwang, T. C.; Sheppard, D. N. Molecular pharmacology of the CFTR Cl- channel. Trends pharmacol. Sci. 1999, 20, 448-453.
110. Liu, H.; Dong, A.; Gao, C.; Tan, C.; Xie, Z.; Zu, X.; Qu, L.; Jiang, Y. New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells. Bioorg. Med. Chem., 2010, 18, 6322-6328.
111. Hunyadi, A.; Chuang, D. W.; Danko, B.; Chiang, M. Y.; Lee, C. L.; Wang, H. C.; Wu, C. C.; Chang, F. R.; Wu, Y. C. Direct semisynthesis of the anticancer lead-drug protoapigenone from apigenin, and synthesis of further new cytotoxic Protoflavone derivatives. PLoS ONE, 2011, 6 (8), e23922, 1-10.
112. Mayo, M. W.; Baldwin, A. S. The transcription factor NF-B: Control of oncogenesis and cancer therapy resistance. Biochimica et Biophysica Acta - Reviews on Cancer, 2000, 1470, M55-M62.
113. Ghosh, S.; Hayden, M. S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8, 837-848.
114. Aggarwal, B. B.; Takada, Y.; Shishodia, S.; Gutierrez, A. M.; Oommen, O. V.; Ichikawa, H.; Baba, Y.; Kumar, A. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J. Exp. Biol., 2004, 42, 341-353.
115. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature, 2006, 441, 431-436.
116. Mauro, C.; Zazzeroni, F.; Papa, S.; Bubici, C.; Franzoso, G. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Methods in molecular biology (Clifton, N.J.), 2009, 512, 169-207.
117. Shin, S. Y.; Woo, Y.; Hyun, J.; Yong, Y.; Koh, D.; Lee, Y. H.; Lim, Y. Relationship between the structures of flavonoids and their NF-κB-dependent transcriptional activities. Bioorg. Med. Chem. Lett., 2011, 21, 6036-6041.
118. Patterson, L. H.; Murray, G. I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des., 2002, 8, 1335-1347.
119. Kuffel, M. J.; Schroeder, J. C.; Pobst, L. J.; Naylor, S.; Reid, J. M.; Kaufmann, S. H.; Ames, M. M. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol. Pharmacol., 2002, 62, 143-153.